Publication 3/01/2017

Nonclinical Pharmacology/Toxicology Study of AAV8.TBG.mLDLR and AAV8.TBG.hLDLR in a Mouse Model of Homozygous Familial Hypercholesterolemia.

Greig JA, Limberis MP, Bell P, Chen SJ, Calcedo R, Rader DJ, Wilson JM

Human Gene Therapy. Clinical Development

Publication 3/01/2017

Non-Clinical Study Examining AAV8.TBG.hLDLR Vector-Associated Toxicity in Chow-Fed Wild-Type and LDLR+/- Rhesus Macaques.

Greig JA, Limberis MP, Bell P, Chen SJ, Calcedo R, Rader DJ, Wilson JM

Human Gene Therapy Clinical Development

Publication 2/14/2017

Class I-restricted T-cell responses to a polymorphic peptide in a gene therapy clinical trial for α-1-antitrypsin deficiency.

Calcedo R, Somanathan S, Qin Q, Betts MR, Rech AJ, Vonderheide RH, Mueller C, Flotte TR, Wilson JM

Proceedings Of The National Academy Of Sciences Of The United States Of America

Publication 12/07/2016

Intramuscular administration of AAV overcomes pre-existing neutralizing antibodies in rhesus macaques.

Greig JA, Calcedo R, Grant RL, Peng H, Medina-Jaszek CA, Ahonkhai O, Qin Q, Roy S, Tretiakova AP, Wilson JM

Vaccine

Publication 6/01/2016

AAV natural infection induces broad cross-neutralizing antibody responses to multiple AAV serotypes in chimpanzees.

Calcedo R, Wilson JM

Human Gene Therapy. Clinical Development

Publication 6/01/2016

AAV Natural Infection Induces Broad Cross-Neutralizing Antibody Responses to Multiple AAV Serotypes in Chimpanzees.

Calcedo R, Wilson JM

Human Gene Therapy. Clinical Development